These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29121201)

  • 1. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
    Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
    J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
    Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
    Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
    Heijckmann AC; Huijberts MS; Geusens P; de Vries J; Menheere PP; Wolffenbuttel BH
    Eur J Endocrinol; 2005 Jul; 153(1):23-9. PubMed ID: 15994742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
    Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
    Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vertebral fracture prevalence among Greek healthy middle-aged postmenopausal women: association with demographics, anthropometric parameters, and bone mineral density.
    Lambrinoudaki I; Flokatoula M; Armeni E; Pliatsika P; Augoulea A; Antoniou A; Alexandrou A; Creatsa M; Panoulis C; Dendrinos S; Papacharalambous X
    Spine J; 2015 Jan; 15(1):86-94. PubMed ID: 25106754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density.
    Mazziotti G; Porcelli T; Patelli I; Vescovi PP; Giustina A
    Bone; 2010 Mar; 46(3):747-51. PubMed ID: 19892039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T; Nery L; Hales I
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
    Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
    Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
    N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
    Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy.
    Vera L; Gay S; Campomenosi C; Paolino S; Pera G; Monti E; Mortara L; Seriolo B; Giusti M
    Endokrynol Pol; 2016; 67(4):350-8. PubMed ID: 27387240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
    Sugitani I; Fujimoto Y
    Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
    Sousa BÉCA; Silva BC; de Oliveira Guidotti T; Pires MC; Soares MMS; Kakehasi AM
    J Endocrinol Invest; 2021 Oct; 44(10):2295-2305. PubMed ID: 33730348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.